Table 1.
Demographics across cohort of patients under 19 years with laboratory confirmation of SARS-CoV-2. Values are numbers (percentages) unless stated otherwise
| Variable | Patients (n=651) |
|---|---|
| Median (interquartile range) age, years | 4.6 (0.3-13.7) |
| Age group: | |
| <1 month | 53 (8.1) |
| 1 month to <1 year | 172 (26.4) |
| 1-4 years | 108 (16.6) |
| 5-9 years | 92 (14.1) |
| 10-14 years | 94 (14.4) |
| 15-19 years | 132 (20.3) |
| Sex at birth: | |
| Male | 367 (56.4) |
| Female | 283 (43.5) |
| Missing | 1 (0.2) |
| Ethnicity: | |
| White | 330 (50.7) |
| Black | 56 (8.6) |
| South Asian | 67 (10.3) |
| Other | 123 (18.9) |
| Missing | 75 (11.5) |
| Admitted >5 days before symptom onset: | |
| No | 538 (82.6) |
| Yes | 55 (8.4) |
| Missing | 58 (8.9) |
| Any comorbidity: | |
| No/unknown | 375 (57.6) |
| Yes | 276 (42.4) |
| Neurological comorbidity: | |
| No | 549 (84.3) |
| Yes | 65 (10.0) |
| Missing | 37 (5.7) |
| Haematological, oncological, immunological comorbidity: | |
| No | 567 (87.1) |
| Yes | 48 (7.4) |
| Missing | 36 (5.5) |
| Asthma: | |
| No | 570 (87.6) |
| Yes | 45 (6.9) |
| Missing | 36 (5.5) |
| Prematurity*: | |
| No | 155 (23.8) |
| Yes | 46 (7.1) |
| Missing | 450 (69.1) |
| Immunosuppressant use before presentation†: | |
| No | 546 (83.9) |
| Yes | 53 (8.1) |
| Missing | 52 (8.0) |
*
Defined as birth before completion of 37 weeks’ gestation.
†
Includes oral but not inhaled corticosteroids.